

Ronald N Hines

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3877196/publications.pdf>

Version: 2024-02-01

94
papers

5,611
citations

87888

38
h-index

88630

70
g-index

97
all docs

97
docs citations

97
times ranked

4391
citing authors

#	ARTICLE	IF	CITATIONS
1	The ontogeny of drug metabolism enzymes and implications for adverse drug events. , 2008, 118, 250-267.		346
2	Developmental Expression of the Major Human Hepatic CYP3A Enzymes. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 573-582.	2.5	345
3	The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative Enzymes: Table 1. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 355-360.	2.5	328
4	The Ontogeny of Human Drug-Metabolizing Enzymes: Phase II Conjugation Enzymes and Regulatory Mechanisms: Table 1. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 361-366.	2.5	325
5	Developmental Expression of Human Hepatic CYP2C9 and CYP2C19. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 965-974.	2.5	291
6	Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression. Pediatric Research, 2002, 51, 236-243.	2.3	224
7	Ontogeny of human hepatic cytochromes P450. Journal of Biochemical and Molecular Toxicology, 2007, 21, 169-175.	3.0	202
8	A Tiered Approach to Life Stages Testing for Agricultural Chemical Safety Assessment. Critical Reviews in Toxicology, 2006, 36, 69-98.	3.9	151
9	A Genetic Polymorphism in the Regulatory Sequences of Human CYP2E1: Association with Increased Chlorzoxazone Hydroxylation in the Presence of Obesity and Ethanol Intake. Toxicology and Applied Pharmacology, 1998, 152, 276-281.	2.8	141
10	Developmental Changes in Human Liver CYP2D6 Expression. Drug Metabolism and Disposition, 2008, 36, 1587-1593.	3.3	138
11	Identification of multiple regulatory elements on the human cytochrome P450IA1 gene. Carcinogenesis, 1988, 9, 1599-1605.	2.8	120
12	Human Hepatic CYP2E1 Expression during Development. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 402-407.	2.5	113
13	Biochemical and Clinical Aspects of the Human Flavin-Containing Monooxygenase Form 3 (FMO3) Related to Trimethylaminuria. Current Drug Metabolism, 2003, 4, 151-170.	1.2	97
14	Developmental Expression of Aryl, Estrogen, and Hydroxysteroid Sulfotransferases in Pre- and Postnatal Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1310-1317.	2.5	97
15	Population-Based Analysis of Methadone Distribution and Metabolism Using an Age-Dependent Physiologically Based Pharmacokinetic Model. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 485-518.	1.8	90
16	Epirubicin Glucuronidation and UGT2B7 Developmental Expression. Drug Metabolism and Disposition, 2006, 34, 2097-2101.	3.3	84
17	Human hepatic CYP2B6 developmental expression: The impact of age and genotype. Biochemical Pharmacology, 2009, 78, 184-190.	4.4	84
18	Alternative Processing of the Human FMO6 Gene Renders Transcripts Incapable of Encoding a Functional Flavin-Containing Monooxygenase. Molecular Pharmacology, 2002, 62, 320-325.	2.3	83

#	ARTICLE	IF	CITATIONS
19	Induction of cytochrome P450 1A1 gene expression, oxidative stress, and genotoxicity by carbaryl and thiabendazole in transfected human HepG2 and lymphoblastoid cells22Abbreviations: AhR, aryl hydrocarbon receptor; CAT, chloramphenicol acetyl transferase; CYP1A1, cytochrome P450 1A1; FBS, fetal bovine serum; GADD, growth arrest and DNA damage; GRP78, 78-kD glucose-regulated protein; GST, glutathione S-transferase; HMTII, human metallothionein II; HSP, heat shock protein; 3-MC,	4.4	81
20	A Chemical Category-Based Prioritization Approach for Selecting 75 Per- and Polyfluoroalkyl Substances (PFAS) for Tiered Toxicity and Toxicokinetic Testing. Environmental Health Perspectives, 2019, 127, 14501.	6.0	75
21	Glucocorticoid regulation of the rat cytochrome P450c (P450IA1) gene: Receptor binding within intron I. Archives of Biochemistry and Biophysics, 1989, 269, 93-105.	3.0	74
22	The NFKB1 (g.-24519delATTG) Variant is Associated with Necrotizing Enterocolitis (NEC) in Premature Infants. Journal of Surgical Research, 2011, 169, e51-e57.	1.6	71
23	Human Hepatic CYP2E1 Expression during Development. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 402-407.	2.5	71
24	Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: II. Expression and Role of Flavin-Containing Monooxygenases and Peroxidases. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 497-505.	2.5	69
25	Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants. Molecular Pharmacology, 2005, 68, 383-392.	2.3	65
26	Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 266-273.	2.5	64
27	Gene structure and nucleotide sequence for rat cytochrome P-450c. Archives of Biochemistry and Biophysics, 1985, 237, 465-476.	3.0	61
28	Variation in Induction of Human Placental CYP2E1: Possible Role in Susceptibility to Fetal Alcohol Syndrome?. Toxicology and Applied Pharmacology, 1997, 144, 396-400.	2.8	59
29	Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics, 2005, 6, 807-822.	1.3	59
30	Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin. Pediatric Research, 2016, 79, 409-415.	2.3	54
31	Implication of the "4S" polycyclic aromatic hydrocarbon binding protein in the transregulation of rat cytochrome P-450c expression. Biochemistry, 1985, 24, 7839-7845.	2.5	51
32	Regulation of DHP receptor expression by elements in the 5â€²-flanking sequence. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H1153-H1162.	3.2	51
33	GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO). Drug Metabolism Reviews, 2002, 34, 523-532.	3.6	50
34	Regulation of cytochrome P-450c by glucocorticoids and polycyclic aromatic hydrocarbons in cultured fetal rat hepatocytes. Archives of Biochemistry and Biophysics, 1986, 246, 439-448.	3.0	48
35	The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines. Drug Metabolism Reviews, 2006, 38, 139-147.	3.6	46
36	A <i>TLR5</i> (g.1174Câ€‰%>â€‰%T) variant that encodes a stop codon (R392X) is associated with bronchopulmonary dysplasia. Pediatric Pulmonology, 2012, 47, 460-468.	2.0	44

#	ARTICLE	IF	CITATIONS
37	Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 1210-1218.	2.5	42
38	Characterization of the Human Lung CYP2F1 Gene and Identification of a Novel Lung-specific Binding Motif. <i>Journal of Biological Chemistry</i> , 2003, 278, 15473-15483.	3.4	40
39	Trichloroethylene Decreases Heat Shock Protein 90 Interactions with Endothelial Nitric Oxide Synthase: Implications for Endothelial Cell Proliferation. <i>Toxicological Sciences</i> , 2003, 73, 90-97.	3.1	40
40	Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny. <i>Drug Metabolism and Disposition</i> , 2016, 44, 959-966.	3.3	39
41	Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 488-496.	2.5	38
42	Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 41-49.	3.3	38
43	Human Hepatic UGT2B15 Developmental Expression. <i>Toxicological Sciences</i> , 2014, 141, 292-299.	3.1	38
44	Approaches for Assessing Risks to Sensitive Populations: Lessons Learned from Evaluating Risks in the Pediatric Population. <i>Toxicological Sciences</i> , 2010, 113, 4-26.	3.1	36
45	Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards. <i>Toxicological Sciences</i> , 2016, 152, 230-243.	3.1	35
46	Hepatobiliary Disposition of 17-OHPC and Taurocholate in Fetal Human Hepatocytes: A Comparison with Adult Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2013, 41, 296-304.	3.3	32
47	Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages. <i>Drug Metabolism and Disposition</i> , 2017, 45, 468-475.	3.3	31
48	DIFFERENCES IN FMO2*1 ALLELIC FREQUENCY BETWEEN HISPANICS OF PUERTO RICAN AND MEXICAN DESCENT. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1337-1340.	3.3	30
49	Prenatal and Postnatal Expression of Glutathione Transferase γ 1 in Human Liver and the Roles of Haplotype and Subject Age in Determining Activity with Dichloroacetate. <i>Drug Metabolism and Disposition</i> , 2012, 40, 232-239.	3.3	30
50	Novel <i>CYP2C9</i> Promoter Variants and Assessment of Their Impact on Gene Expression. <i>Molecular Pharmacology</i> , 2008, 73, 1751-1760.	2.3	29
51	Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans. <i>Toxicological Sciences</i> , 2020, 173, 86-99.	3.1	29
52	Altered Regulation of the Cytochrome P4501A1 Gene: Novel Inducer-Independent Gene Expression in Pulmonary Carcinoma Cell Lines. <i>Journal of the National Cancer Institute</i> , 1989, 81, 1787-1794.	6.3	28
53	Interaction of the 4 S polycyclic aromatic hydrocarbon-binding protein with the cytochrome P-450c gene. <i>Archives of Biochemistry and Biophysics</i> , 1987, 259, 215-223.	3.0	27
54	NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2004, 71, 193-280.	1.4	27

#	ARTICLE	IF	CITATIONS
55	Regulation of Flavin-Containing Monooxygenase 1 Expression by Ying Yang 1 and Hepatic Nuclear Factors 1 and 4. <i>Molecular Pharmacology</i> , 2001, 60, 1421-1430.	2.3	26
56	Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. <i>Toxicology and Applied Pharmacology</i> , 2003, 186, 119-126.	2.8	26
57	Two distinct classes of CCAAT box elements that bind nuclear factor-Y/?-actinin-4: potential role in human CYP1A1 regulation. <i>Toxicology and Applied Pharmacology</i> , 2004, 199, 239-250.	2.8	25
58	Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 245-256.	1.5	24
59	Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/enhancer-binding protein 1 ² (C/EBP1 ²) liver inhibitory and liver activating proteins. <i>Biochemical Pharmacology</i> , 2008, 76, 268-278.	4.4	24
60	Developmental Expression of the Cytosolic Sulfotransferases in Human Liver. <i>Drug Metabolism and Disposition</i> , 2019, 47, 592-600.	3.3	24
61	Developmental regulation of flavin-containing monooxygenase (FMO) isoforms 1 and 2 in pregnant rabbit. <i>Chemico-Biological Interactions</i> , 1995, 96, 75-85.	4.0	23
62	Mechanisms Regulating Human FMO3 Transcription. <i>Drug Metabolism Reviews</i> , 2007, 39, 419-442.	3.6	23
63	The molecular cloning of cytochrome P-450c information. <i>Archives of Biochemistry and Biophysics</i> , 1981, 212, 501-507.	3.0	22
64	3-Methylcholanthrene-induced expression of the cytochrome P-450c gene. <i>Archives of Biochemistry and Biophysics</i> , 1985, 239, 137-146.	3.0	22
65	Tolerance to Acetaminophen Hepatotoxicity in the Mouse Model of Autoprotection Is Associated with Induction of Flavin-Containing Monooxygenase-3 (FMO3) in Hepatocytes. <i>Toxicological Sciences</i> , 2014, 141, 263-277.	3.1	22
66	Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. <i>Drug Metabolism and Disposition</i> , 2016, 44, 999-1004.	3.3	22
67	FutureTox III: Bridges for Translation. <i>Toxicological Sciences</i> , 2017, 155, 22-31.	3.1	22
68	Developmental regulation of the L-type calcium channel alpha1C subunit expression in heart. <i>Molecular and Cellular Biochemistry</i> , 2000, 205, 101-109.	3.1	21
69	Genetics and Susceptibility to Toxic Chemicals: Do You (or Should You) Know Your Genetic Profile?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 403-409.	2.5	21
70	Differences in 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible CYP1A1 expression in human breast carcinoma cell lines involve altered trans-acting factors. <i>FEBS Journal</i> , 1991, 197, 577-582.	0.2	20
71	SP1 AND SP3 REGULATE BASAL TRANSCRIPTION OF THE HUMAN CYP2F1 GENE. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1244-1253.	3.3	20
72	Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition. <i>Drug Metabolism Reviews</i> , 2008, 40, 263-301.	3.6	20

#	ARTICLE	IF	CITATIONS
73	Baseline Chromatin Modification Levels May Predict Interindividual Variability in Ozone-Induced Gene Expression. <i>Toxicological Sciences</i> , 2016, 150, 216-224.	3.1	20
74	Application of epigenetic data in human health risk assessment. <i>Current Opinion in Toxicology</i> , 2017, 6, 71-78.	5.0	19
75	Molecular induction by phenobarbital of a rat hepatic form of cytochrome P-450: Expression of a 4-kilobase messenger RNA. <i>Archives of Biochemistry and Biophysics</i> , 1983, 227, 478-493.	3.0	17
76	MOLECULAR MECHANISMS REGULATING HUMAN CYP4B1 LUNG-SELECTIVE EXPRESSION. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1174-1184.	3.3	16
77	Pharmacogenomics and the Future of Drug Therapy. <i>Pediatric Clinics of North America</i> , 2006, 53, 591-619.	1.8	16
78	Identification of Multiple Rabbit Flavin-Containing Monooxygenase Form 1 (FMO1) Gene Promoters and Observation of Tissue-Specific DNase I Hypersensitive Sites. <i>Archives of Biochemistry and Biophysics</i> , 1996, 336, 251-260.	3.0	15
79	Human and environmental health challenges for the next decade (2010–2020). <i>Critical Reviews in Toxicology</i> , 2010, 40, 893-911.	3.9	15
80	CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. <i>Blood</i> , 2003, 101, 2896-2896.	1.4	14
81	In vitro binding and functional studies comparing the human CYP1A1 negative regulatory element with the orthologous sequences from rodent genes. <i>Carcinogenesis</i> , 1995, 16, 383-392.	2.8	13
82	Identification and Functional Analysis of a Novel Human CYP2E1 Far Upstream Enhancer. <i>Molecular Pharmacology</i> , 2007, 71, 1630-1639.	2.3	10
83	Further Characterization of the Major and Minor Rabbit FMO1 Promoters and Identification of both Positive and Negative Distal Regulatory Elements. <i>Archives of Biochemistry and Biophysics</i> , 1997, 346, 96-104.	3.0	7
84	Oxidative stress-responsive transcription factor NRF2 is not indispensable for the human hepatic Flavin-containing monooxygenase-3 (FMO3) gene expression in HepG2 cells. <i>Toxicology in Vitro</i> , 2016, 31, 54-59.	2.4	7
85	A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes. <i>Chemical Research in Toxicology</i> , 2019, 32, 1707-1721.	3.3	6
86	Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2016, 21, 224-232.	0.5	5
87	Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1027-1037.	3.3	5
88	The Impact of Scaling Factor Variability on Risk-Relevant Pharmacokinetic Outcomes in Children: A Case Study Using Bromodichloromethane (BDCM). <i>Toxicological Sciences</i> , 2019, 167, 347-359.	3.1	5
89	Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids. <i>Toxicological Sciences</i> , 2020, 176, 460-469.	3.1	5
90	Bringing Big Data to Bear in Environmental Public Health: Challenges and Recommendations. <i>Frontiers in Artificial Intelligence</i> , 2020, 3, .	3.4	5

#	ARTICLE	IF	CITATIONS
91	Inhibition of metabolism-mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma (line p815) cells. <i>Biochemical Pharmacology</i> , 1982, 31, 2921-2928.	4.4	4
92	PUBLICATION OF STAND-ALONE SINGLE NUCLEOTIDE POLYMORPHISM (SNP) DISCOVERY DATA. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1073-1073.	3.3	0
93	Novel Hispanic American <i>CYP2C9</i> Genetic Variants and Assessment of Their Impact on Gene Expression. <i>FASEB Journal</i> , 2007, 21, A415.	0.5	0
94	Pharmacogenetic Testing in the Pediatric Epileptic Population. <i>FASEB Journal</i> , 2010, 24, .	0.5	0